A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

 
Web www.patentalert.com

< Amphiphilic polymers and polypeptide conjugates comprising same

< Spiro-indolines as Y5 receptor antagonists

> Endogenous constitutively activated G protein-coupled orphan receptors

> C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals

~ 00091